1-9 of 9
Hiroshi Ureshino
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

An Open-Label, Multicenter, Single-Arm, Phase I Dose Escalation Study of OP-2100, an Orally Bioavailable Prodrug of Decitabine, for Patients with Relapsed or Refractory Higher-Risk Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia

Shinya Kimura, Kensuke Usuki, Tatsuo Ichinohe, Takayuki Ikezoe, Junya Kuroda, Senji Kasahara, Sho Okamoto, Hiromitsu Iizuka, Hiroshi Ureshino, Tatsuro Watanabe, Tokihiro Ro, Kosuke Endo, Yuka Kagawa, Yuki Kurahashi, Toshiki Naito, Takahiro Yamauchi
Journal: Blood
Blood (2023) 142 (Supplement 1): 6466.
https://doi.org/10.1182/blood-2023-173174
Published: 2023
Journal Articles

Platinum Talen-Mediated Knock-in of Single-Stranded DNA Templates Facilitates Manufacturing of Clinical-Scale Non-Virally Gene-Edited T Cells from Peripheral Blood

Kayo Toishigawa, Taro Edahiro, Kenta Magoori, Hiroyuki Sato, Saori Fukunaga, Yemima Suryani Budirahardja, Hiroshi Ureshino, Ryuji Suzuki, Tetsushi Sakuma, Takashi Yamamoto, Tatsuo Ichinohe
Journal: Blood
Blood (2023) 142 (Supplement 1): 6794.
https://doi.org/10.1182/blood-2023-178451
Published: 2023
Journal Articles

A Novel Anticancer Quinolone, ( R )-Wac-224 Monotherapy or Combination with Cytarabine/Venetoclax Confers Promising Activities Against Acute Myeloid Leukemia

Tatsuji Mino, Hiroshi Ureshino, Taichi Ueshima, Naoki Kashimoto, Tomonori Yamaguchi, Miyuki Takashima, Yusuke Sanuki, Kazuhito Naka, Toshiya Inaba, Tatsuo Ichinohe
Journal: Blood
Blood (2023) 142 (Supplement 1): 5775.
https://doi.org/10.1182/blood-2023-175075
Published: 2023
Journal Articles

Lower-Initiating Dose of Bosutinib for Resistant or Intolerant to Prior Therapy Chronic Myeloid Leukemia Patients (BOGI trial): A Single-Arm, Multicenter, Phase II Trial

Hiroshi Ureshino, Naoto Takahashi, Takayuki Ikezoe, Ayako Takamori, Atsushi Kawaguchi, Tatsuo Ichinohe, Shinya Kimura
Journal: Blood
Blood (2023) 142 (Supplement 1): 3179.
https://doi.org/10.1182/blood-2023-174594
Published: 2023
Journal Articles

Very Low-Dose Dasatinib Is a Safe and Effective Therapy for Elderly Patients with Newly-Diagnosed Chronic-Phase Chronic Myeloid Leukemia: Results from the Davlec Study, a Single-Arm, Multicenter, Phase 2 Trial

Takashi Kumagai, Kazunori Murai, Hiroshi Ureshino, Hideo Tanaka, Kaichi Nishiwaki, Satoshi Wakita, Koiti Inokuchi, Toshihiro Fukushima, Chikashi Yoshida, Masayuki Mita, Nobuhiko Uoshima, Toru Kiguchi, Jun Aoki, Satoshi Kimura, Kaori Karimata, Kensuke Usuki, Joji Shimono, Yoshiaki Chinen, Junya Kuroda, Yasufumi Matsuda, Kensuke Nakao, Takaaki Ono, Katsumichi Fujimaki, Hirohiko Shibayama, Chisaki Mizumoto, Tomoharu Takeoka, Katsuhiro Io, Takeshi Kondo, Masatomo Miura, Yosuke Minami, Takayuki Ikezoe, Jun Imagawa, Ayako Takamori, Atsushi Kawaguchi, Junichi Sakamoto, Shinya Kimura
Journal: Blood
Blood (2021) 138 (Supplement 1): 3601.
https://doi.org/10.1182/blood-2021-149483
Published: 2021
Journal Articles

Targeting aberrant DNA hypermethylation as a driver of ATL leukemogenesis by using the new oral demethylating agent OR-2100

Tatsuro Watanabe, Satoshi Yamashita, Hiroshi Ureshino, Kazuharu Kamachi, Yuki Kurahashi, Yuki Fukuda-Kurahashi, Nao Yoshida, Naoko Hattori, Hideaki Nakamura, Akemi Sato, Atsushi Kawaguchi, Naoko Sueoka-Aragane, Kensuke Kojima, Seiji Okada, Toshikazu Ushijima, Shinya Kimura, Eisaburo Sueoka
Journal: Blood
Blood (2020) 136 (7): 871–884.
https://doi.org/10.1182/blood.2019003084
Published: 2020
Includes: Supplemental data
Journal Articles

Efficacy of OR21, a Novel Oral Demethylating Agent in Chronic Myeloid Leukemia

Kazuharu Kamachi, MD, Hiroshi Ureshino, MD, Nao Yoshida, MD, Yuki Kurahashi, Tatsuro Watanabe, PhD, Seiji Okada, MD PhD, Shinya Kimura, MD PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 5365.
https://doi.org/10.1182/blood-2019-125460
Published: 2019
Journal Articles

Aberrant Regional DNA Hypermethylation As a Preventive and Therapeutic Target for Adult T-Cell Leukemia-Lymphoma

Tatsuro Watanabe, PhD, Hiroshi Ureshino, MD, Yuki Kurahashi, Yuki Fukuda-Kurahashi, Satoshi Yamashita, PhD, Toshikazu Ushijima, MD PhD, Seiji Okada, MD PhD, Eisaburo Sueoka, MD PhD, Shinya Kimura, MD PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 4175.
https://doi.org/10.1182/blood-2018-99-117536
Published: 2018
Journal Articles

OR21, a New Oral DNA Methyltransferase Inhibitor for Treatment of MDS and AML

Hiroshi Ureshino, MD, Tatsuro Watanabe, PhD, Yuki Kurahashi, Yuki Fukuda Kurahashi, Kaoru Tohyama, MD, Seiji Okada, MD PhD, Toshikazu Ushijima, MD PhD, Hiroshi Ureshino, MD PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 5499.
https://doi.org/10.1182/blood-2018-99-112362
Published: 2018